Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)

This publication has 33 references indexed in Scilit:

• Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
  Kidney International, 2002
• Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
  American Journal of Kidney Diseases, 2000
• Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients*
  Nephrology Dialysis Transplantation, 1999
• A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
  American Journal of Kidney Diseases, 1999
• RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
  Kidney International, 1999
• Effect of RenaGel(R), a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients
  Nephrology Dialysis Transplantation, 1998
• Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
  American Journal of Kidney Diseases, 1998
• Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
  American Journal of Kidney Diseases, 1997
• The contribution of acidosis to renal osteodystrophy
  Kidney International, 1995
• The Dialysis Encephalopathy Syndrome
  New England Journal of Medicine, 1976